Cladribine Treatment Outcomes
| Patient No. . | Response . | Response Duration (mos) . | No. of Cladribine Courses . | Toxicities/Late Events . | Status (follow-up in months) . |
|---|---|---|---|---|---|
| 1 | CR | 65+ | 4 | Grade 4 neutropenia with fever | Alive (76) |
| Recurrence of papillary carcinoma of thyroid | |||||
| 2 | CR | 36 | 2 | Chronic myelomonocytic leukemia | Dead (41) |
| 3 | NR | — | 3 | Grade 3 neutropenia | Alive (39) |
| 4 | CR | 46+ | 2 | Grade 4 neutropenia | Alive (49) |
| 5 | CR (Pathologic) | 5 | 3 | Alive (47) | |
| 6 | CR | 33+ | 6 | Grade 3 neutropenia | Alive (48) |
| 7 | CR (Pathologic) | 1 | 6 | Alive (47) | |
| 8 | CR | 10+ | 6 | Alive (45) | |
| 9 | PR | 36+ | 6 | Grade 4 neutropenia with fever | Alive (42) |
| 10 | NR | — | 2 | Grade 4 neutropenia | Alive (32) |
| 11 | NE | — | 1 | Possible acute allergic reaction to cladribine | Alive (16) |
| 12 | PR | 8+ | 6 | Grade 4 neutropenia | Alive (15) |
| 13 | NR | — | 3 | Alive (6) |
| Patient No. . | Response . | Response Duration (mos) . | No. of Cladribine Courses . | Toxicities/Late Events . | Status (follow-up in months) . |
|---|---|---|---|---|---|
| 1 | CR | 65+ | 4 | Grade 4 neutropenia with fever | Alive (76) |
| Recurrence of papillary carcinoma of thyroid | |||||
| 2 | CR | 36 | 2 | Chronic myelomonocytic leukemia | Dead (41) |
| 3 | NR | — | 3 | Grade 3 neutropenia | Alive (39) |
| 4 | CR | 46+ | 2 | Grade 4 neutropenia | Alive (49) |
| 5 | CR (Pathologic) | 5 | 3 | Alive (47) | |
| 6 | CR | 33+ | 6 | Grade 3 neutropenia | Alive (48) |
| 7 | CR (Pathologic) | 1 | 6 | Alive (47) | |
| 8 | CR | 10+ | 6 | Alive (45) | |
| 9 | PR | 36+ | 6 | Grade 4 neutropenia with fever | Alive (42) |
| 10 | NR | — | 2 | Grade 4 neutropenia | Alive (32) |
| 11 | NE | — | 1 | Possible acute allergic reaction to cladribine | Alive (16) |
| 12 | PR | 8+ | 6 | Grade 4 neutropenia | Alive (15) |
| 13 | NR | — | 3 | Alive (6) |
Abbreviations: CR, complete response; PR, partial response; NR, no response; NE, not evaluable.